Healthcare / BiotechnologyKOSDAQ
$10430.00
+110.00 (+1.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.7B · quality 83.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$89.0B
P/E
13.4x
↓EV/EBITDA
8.4x
↓ROE
9.6%
↑Gross Margin
67.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.5%
FCF CAGR
+5.2%
FCF margin
32.5%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.18B · net income $6.67B · FCF $6.23B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.18B | $19.18B | $16.07B | $15.59B | $15.86B |
| Net Income | $6.67B | $6.67B | $4.50B | $5.59B | $4.34B |
| EBITDA | $9.31B | $9.31B | $6.50B | $8.37B | $6.60B |
| EPS | 781.00 | 781.00 | 528.00 | 655.00 | 492.00 |
| Gross Margin | 67.1% | 67.1% | 69.8% | 70.7% | 69.4% |
| Operating Margin | 32.6% | 32.6% | 30.2% | 32.3% | 30.8% |
| Net Margin | 34.8% | 34.8% | 28.0% | 35.8% | 27.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.06 |
| Current Ratio | 17.86 | 17.86 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.23B | $6.23B | $4.74B | $3.72B | $5.35B |
| Returns | |||||
| ROE | 9.6% | 9.6% | 7.1% | 9.5% | 8.2% |
| Valuation | |||||
| P/E | 13.35 | 13.35 | 26.52 | 22.81 | 36.28 |
| EV/EBITDA | 8.44 | 8.44 | 17.38 | 13.95 | 22.62 |
| P/B | 1.28 | 1.28 | 1.89 | 2.17 | 2.97 |
| Growth & Yield | |||||
| Revenue Growth | 19.4% | 19.4% | 3.0% | -1.7% | — |
| EPS Growth | 47.9% | 47.9% | -19.4% | 33.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.8%
EPS terminal req.
$925.49
Spread vs growth
42.1%
5Y implied EPS CAGR
7.5%
EPS terminal req.
$1119.84
Spread vs growth
40.4%
10Y implied EPS CAGR
8.7%
EPS terminal req.
$1803.52
Spread vs growth
39.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.5%
Start / end P/E
28.0x → 13.4x
EPS bridge
528.00 → 781.00
Residual
-25.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.